Browse Category

NASDAQ:SXTP News 22 January 2026 - 23 January 2026

60 Degrees Pharmaceuticals stock swings again: SXTP slides in premarket after Runway Health deal pop

60 Degrees Pharmaceuticals shares fell 9.9% to $4.54 in Friday premarket trading, after soaring 152% the previous session on news of a Runway Health partnership to launch telehealth sales of its malaria pill ARAKODA starting April 2. The company executed a 1-for-4 reverse stock split on Jan. 20 to meet Nasdaq listing requirements.

23 January 2026

NASDAQ:SXTP·Pharmaceuticals·Stock Market

60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

Shares of 60 Degrees Pharmaceuticals (SXTP) jumped 267% to $7.34 Thursday after announcing a distribution deal with Runway Health for its malaria drug ARAKODA. Trading volume soared to nearly 116 million shares. The agreement will allow online consultations and home delivery starting April 2. A 1-for-4 reverse stock split took effect earlier this week.

22 January 2026

NASDAQ:SXTP·Pharmaceuticals

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

7 February 2026

Alphabet Class C shares (GOOG) fell 2.48% to $323.10 Friday after the company projected 2026 capital spending of up to $185 billion, more than double 2025 levels. CEO Sundar Pichai sold 32,500 shares earlier in the week under a pre-set plan. The Dow closed above 50,000 for the first time. Over 33.9 million GOOG shares traded, above recent volume.

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026

Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.

Liberty Global stock ends higher as Class B shares spike, with earnings next on deck

7 February 2026

Liberty Global’s Class B shares jumped as much as 139% Friday in heavy trading, while Class A shares rose 4.3% to $11.75. The move came ahead of full-year results due Feb. 18 and followed news of a five-year Google Cloud partnership and reports of advanced talks to buy UK broadband provider Netomnia.

Go toTop

NASDAQ:SXTP News 22 January 2026 - 23 January 2026

60 Degrees Pharmaceuticals stock swings again: SXTP slides in premarket after Runway Health deal pop

60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

Stock Market Today

GOOG stock price: Alphabet’s $185 billion AI spend plan keeps Google shares on edge into Monday

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Liberty Global stock ends higher as Class B shares spike, with earnings next on deck